ImmuCell Corporation (ICCC)
NASDAQ: ICCC · Real-Time Price · USD
10.02
+0.18 (1.83%)
Aug 26, 2026, 4:00 PM EDT - Market closed
ImmuCell Employees
ImmuCell had 73 employees as of December 31, 2025. The number of employees decreased by 2 or -2.67% compared to the previous year.
Employees
73
Change
-2
Growth
-2.67%
Revenue / Employee
$420,213
Profits / Employee
$10,786
Market Cap
91.00M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Adicet Bio | 102 |
| Fortress Biotech | 78 |
| Acrivon Therapeutics | 76 |
| Verrica Pharmaceuticals | 76 |
| Gain Therapeutics | 21 |
| Cingulate | 14 |
| MAIA Biotechnology | 13 |
| Dogwood Therapeutics | 8 |
ICCC News
- 12 days ago - ImmuCell Earnings Call Transcript: Q2 2026 - Transcripts
- 12 days ago - ImmuCell Earnings release: Q2 2026 - Filings
- 12 days ago - ImmuCell Quarterly report: Q2 2026 - Filings
- 12 days ago - ImmuCell Slides: Q2 2026 - Filings
- 13 days ago - ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026 - GlobeNewsWire
- 14 days ago - ImmuCell Slides: Investor presentation - Filings
- 20 days ago - ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026 - GlobeNewsWire
- 6 weeks ago - Immucell reports preliminary Q2 revenue $7.2M - TheFly